Fig 2: The correlation between the expression of NAA50 and prognosis of cancers by using GEPIA database. (A–G) The correlation between NAA50 expression and Overall survival. (H–L) The correlation between NAA50 expression and cancer stage.

Fig 3: Associations between the NAA50 expression and immune subtypes across human cancers.

Fig 4: Single-Cell Analysis of NAA50 and NAA50-related gene enrichment analysis. (A) The correlation between NAA50 expression and cancer functional states in pan-cancer. (B) The top 50 genes positively correlated to NAA50. (C) The top 50 genes negatively correlated to NAA50. (D) GO (biological function) analysis of NAA50 co-expression genes in the LUAD cohort. (E) KEGG analysis of NAA50 co-expression genes in the LUAD cohort.

Fig 5: Mutation and Methylation feature of NAA50 in different cancers. (A) Alteration frequency with the mutation type of NAA50 in pan-cancer. (B) The subtypes and distributions of NAA50 somatic mutations. (C) The differential DNA methylation level of NAA50 promoter in pan-cancer.